DE60224310D1 - Verfahren zur Herstellung von virusinaktiviertem humanem Gammaglobulin G - Google Patents

Verfahren zur Herstellung von virusinaktiviertem humanem Gammaglobulin G

Info

Publication number
DE60224310D1
DE60224310D1 DE60224310T DE60224310T DE60224310D1 DE 60224310 D1 DE60224310 D1 DE 60224310D1 DE 60224310 T DE60224310 T DE 60224310T DE 60224310 T DE60224310 T DE 60224310T DE 60224310 D1 DE60224310 D1 DE 60224310D1
Authority
DE
Germany
Prior art keywords
gamma globulin
human gamma
inactivated human
producing virus
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60224310T
Other languages
English (en)
Other versions
DE60224310T2 (de
Inventor
Debart Pere Ristol
Gimenez Francisco Rabaneda
Hernandez Teresa Lopez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols SA filed Critical Grifols SA
Publication of DE60224310D1 publication Critical patent/DE60224310D1/de
Application granted granted Critical
Publication of DE60224310T2 publication Critical patent/DE60224310T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60224310T 2001-01-17 2002-01-11 Verfahren zur Herstellung von virusinaktiviertem humanem Gammaglobulin G Expired - Lifetime DE60224310T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200100101 2001-01-17
ES200100101A ES2184594B1 (es) 2001-01-17 2001-01-17 Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.

Publications (2)

Publication Number Publication Date
DE60224310D1 true DE60224310D1 (de) 2008-02-14
DE60224310T2 DE60224310T2 (de) 2009-01-08

Family

ID=8496419

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60224310T Expired - Lifetime DE60224310T2 (de) 2001-01-17 2002-01-11 Verfahren zur Herstellung von virusinaktiviertem humanem Gammaglobulin G

Country Status (14)

Country Link
US (1) US6875848B2 (de)
EP (1) EP1225180B1 (de)
JP (1) JP4070468B2 (de)
AR (1) AR032242A1 (de)
AT (1) ATE382631T1 (de)
CZ (1) CZ300413B6 (de)
DE (1) DE60224310T2 (de)
ES (2) ES2184594B1 (de)
HK (1) HK1048324B (de)
HU (1) HU228252B1 (de)
MX (1) MXPA02000639A (de)
PT (1) PT1225180E (de)
SK (1) SK287633B6 (de)
UY (1) UY27126A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003262087B2 (en) 2002-09-11 2010-11-11 Chugai Seiyaku Kabushiki Kaisha Protein purification method
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
EP3673919A1 (de) 2005-06-14 2020-07-01 Amgen Inc. Selbstpuffernde proteinformulierungen
US20070049732A1 (en) * 2005-09-01 2007-03-01 Zurlo Eugene J Ultra-high yield intravenous immune globulin preparation
US8293242B2 (en) * 2005-09-01 2012-10-23 Plasma Technologies, Llc Ultra-high yield of alpha-1-anti-trypsin
US7879332B2 (en) * 2005-09-01 2011-02-01 Plasma Technologies, Llc Ultra-high yield intravenous immune globulin preparation
JP2008094722A (ja) * 2006-10-05 2008-04-24 Benesis Corp 免疫グロブリン製剤の製造方法
US20080214795A1 (en) * 2007-02-14 2008-09-04 Amgen Inc. Method of isolating antibodies by precipitation
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US10662237B2 (en) 2009-08-06 2020-05-26 Genentech, Inc. Method to improve virus filtration capacity
EP2477603B1 (de) 2009-09-17 2016-03-30 Baxalta Incorporated Stabile co-formulierung von hyaluronidase und immunoglobulin, verfahren zu dessen herstellung und verwendung
RU2558367C2 (ru) * 2010-03-10 2015-08-10 Ф. Хоффманн-Ля Рош Аг Способ очистки полипептидных растворов
US20130172536A1 (en) * 2011-08-16 2013-07-04 Shenzhen Weiguang Biological Products Co.,Ltd. Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof
ES2381828B1 (es) * 2012-03-20 2012-11-16 Grifols, S.A. PROCEDIMIENTO PARA OBTENER UNA COMPOSICION DE IgG MEDIANTE TRATAMIENTO TERMICO
EP3131589B1 (de) 2014-04-15 2023-05-17 Boehringer Ingelheim International GmbH Verfahren und gebrauch zur kontinuierlichen inaktivierung eines virus bei der herstellung eines biologischen produktes
EP3154597B1 (de) * 2014-06-12 2019-01-30 Biosyn Arzneimittel GmbH Herstellungsverfahren für eine neuartige generation an biologisch sicheren klh-produkten zur krebsbehandlung, zur entwicklung von konjugierten therapeutischen impfstoffen und als prüfmittel
CA2951735C (en) 2014-06-12 2020-06-30 Biosyn Arzneimittel Gmbh Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents
JP6521351B2 (ja) 2014-10-14 2019-05-29 テックプロジェクトサービス株式会社 ウィルス不活化およびサンプリング装置
MX2017005148A (es) 2014-11-06 2017-08-08 Hoffmann La Roche Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
PL3135687T3 (pl) 2015-08-31 2019-09-30 Instituto Grifols, S.A. Sposób wytwarzania immunoglobulin
KR20180101583A (ko) 2016-02-03 2018-09-12 플라즈마 테크놀로지스, 엘엘씨 혈액 기반 물질로부터 단백질을 추출하기 위한 방법(methods for extracting proteins from a blood-based material)
SG11201807824UA (en) 2016-03-11 2018-10-30 Boehringer Ingelheim Int Methods for continuously inactivating a virus during manufacture of a protein
KR102372105B1 (ko) * 2016-09-26 2022-03-07 인스티투토 그리폴스, 에스.아. 면역글로블린의 제조방법
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
US10815270B1 (en) 2019-09-20 2020-10-27 Plasma Technologies, Llc Compositions and methods for high efficiency protein precipitation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164495A (en) * 1976-04-06 1979-08-14 Nordisk Insulinlaboratorium Method of recovering immunoglobulin using a polyol and an alkanoic acid
US4374763A (en) * 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
EP0116571B2 (de) * 1982-08-30 1997-10-29 BAXTER INTERNATIONAL INC. (a Delaware corporation) Verfahren zur herstellung von gamma-globulin enthaltenden zusammensetzungen
US5234685A (en) * 1983-03-16 1993-08-10 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Method of determining incompatibility-reaction-causing substances in blood products as well as a method of inactivating said incompatibility-reaction-causing substances
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
DK0659767T4 (da) * 1993-12-27 2003-02-10 Zlb Bioplasma Ag Fremgangsmåde til fremstilling af et koncentrat af anti-D-immunoglobulin G og et farmaceutisk præparat, som indeholder dette
CA2232420A1 (en) * 1997-03-19 1998-09-19 The Green Cross Corporation Immunoglobulin preparation and preparation process thereof
IL121900A (en) * 1997-10-07 2001-12-23 Omrix Biopharmaceuticals Ltd A method for the purification of immunoglobulins
CN1520885A (zh) * 1997-10-23 2004-08-18 ������ҩ��ʽ���� 可室温贮存的免疫球蛋白静脉注射制剂
UA64742C2 (uk) * 1997-12-24 2004-03-15 Альфа Терапевтик Корпорейшн СПОСІБ ОДЕРЖАННЯ РОЗЧИНУ <font face="Symbol">g</font>-ГЛОБУЛІНУ, ПРИЗНАЧЕНОГО ДЛЯ ВНУТРІШНЬОВЕННОГО ВВЕДЕННЯ, І ПРОДУКТ, ЩО ОДЕРЖУЄТЬСЯ У ЦЕЙ СПОСІБ (ВАРІАНТИ)
US6281336B1 (en) * 1998-06-09 2001-08-28 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
PL196770B1 (pl) * 1998-06-09 2008-01-31 Statens Seruminstitut Sposób oczyszczania immunoglobuliny, produkt immunoglobuliny i jego zastosowanie
US6441144B1 (en) * 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration

Also Published As

Publication number Publication date
HU228252B1 (en) 2013-02-28
ES2295308T3 (es) 2008-04-16
EP1225180A3 (de) 2004-01-28
EP1225180B1 (de) 2008-01-02
HK1048324B (zh) 2008-02-22
MXPA02000639A (es) 2004-11-01
SK582002A3 (en) 2002-10-08
UY27126A1 (es) 2002-07-31
US20020151688A1 (en) 2002-10-17
HK1048324A1 (en) 2003-03-28
PT1225180E (pt) 2008-03-18
SK287633B6 (sk) 2011-04-05
DE60224310T2 (de) 2009-01-08
US6875848B2 (en) 2005-04-05
HU0200103D0 (en) 2002-03-28
CZ300413B6 (cs) 2009-05-13
ES2184594B1 (es) 2004-01-01
ES2184594A1 (es) 2003-04-01
EP1225180A2 (de) 2002-07-24
JP2003002896A (ja) 2003-01-08
CZ2002131A3 (cs) 2002-09-11
HUP0200103A3 (en) 2004-10-28
HUP0200103A2 (hu) 2003-08-28
AR032242A1 (es) 2003-10-29
JP4070468B2 (ja) 2008-04-02
ATE382631T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
DE60224310D1 (de) Verfahren zur Herstellung von virusinaktiviertem humanem Gammaglobulin G
DE60221399D1 (de) Verfahren zur herstellung von mitteldistillaten
ATE403641T1 (de) Verfahren zur herstellung von o- desmethylvenlafaxin
ATE468309T1 (de) Verfahren zur herstellung von olefinen
DE60233386D1 (de) Verfahren zur herstellung von halbleiterkristallen und halbleiter-leuchtelementen
DE60237184D1 (de) Verfahren zur Erzeugung von Bewegungen
DE60217489D1 (de) Verfahren zur herstellung von vollfarbenen anzeigetafeln
DE60230908D1 (de) Verfahren zur herstellung von polyarylenethern
ATA11912002A (de) Verfahren zur herstellung von fälschungssicheren identifikationsmerkmalen
ATE286011T1 (de) Verfahren zur herstellung von 1-octen
ATE374463T1 (de) Verfahren zur herstellung von oxazolidinonen
DE60227372D1 (de) Verfahren zur herstellung von harzlinsen
ATE315099T1 (de) Verfahren zur herstellung von tagatose
ATE448209T1 (de) Verfahren zur herstellung von pyrimidinverbindungen
DE50308650D1 (de) Verfahren zur herstellung von cellulosecarbamatformkörpern
ATE296287T1 (de) Verfahren zur herstellung von repaglinide
ATE456569T1 (de) Verfahren zur herstellung von 6-alkyliden- penemderivaten
ATE297430T1 (de) Verfahren zur herstellung von tannin und seine verwendung
ATE441662T1 (de) Verfahren zur herstellung von echinocandinderivaten
ATE553103T1 (de) Verfahren zur herstellung von (s)-pantoprazol
DE60210911D1 (de) Verfahren zur Herstellung von dehnungserfassenden Vorrichtungen
ATE336478T1 (de) Verfahren zur herstellung von benzophenonen
DE50303611D1 (de) Verfahren zur herstellung von polyisobuten
ATE273315T1 (de) Verfahren zur herstellung von n- phosphonomethyliminodiessigsäure
DE50200870D1 (de) Verfahren zur herstellung von hydroxyalkylpolysiloxanen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition